153 related articles for article (PubMed ID: 26288957)
1. Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus.
Watanabe R; Ishii T; Harigae H
Tohoku J Exp Med; 2015 Sep; 237(1):9-15. PubMed ID: 26288957
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy.
Watanabe R; Ishii T; Nakamura K; Shirai T; Tajima Y; Fujii H; Harigae H
Mod Rheumatol; 2013 Nov; 23(6):1094-100. PubMed ID: 23180323
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey.
Watanabe R; Ishii T; Kobayashi H; Asahina I; Takemori H; Izumiyama T; Oguchi Y; Urata Y; Nishimaki T; Chiba K; Komatsuda A; Chiba N; Miyata M; Takagi M; Kawamura O; Kanno T; Hirabayashi Y; Konta T; Ninomiya Y; Abe Y; Murata Y; Saito Y; Ohira H; Harigae H; Sasaki T
Tohoku J Exp Med; 2014 Jun; 233(2):129-33. PubMed ID: 24898712
[TBL] [Abstract][Full Text] [Related]
4. Frequency of Hepatitis B Markers in Systemic Lupus Erythematosus Patients in Iran.
Makvandi M; Noormandi Pour S; Teimoori A; Shokri S; Mahmoudvand S; Biparva Haghighi S; Rajaee E
Asian Pac J Cancer Prev; 2022 Jun; 23(6):1921-1926. PubMed ID: 35763632
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Chronic Hepatitis B Infection in Patients with Systemic Lupus Erythematosus: Viral Reactivation and Impact on Disease Activity.
Sumethkul K; Srivitidkul S
J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S124-30. PubMed ID: 29927230
[TBL] [Abstract][Full Text] [Related]
6. PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT.
Baghbanian M; Halvani M; Roghani HS; Lotfi MH; Yazdi MF; Vahedian-Ardakani HA
Arq Gastroenterol; 2016; 53(3):175-9. PubMed ID: 27438423
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis of hepatitis B reactivation with immunosuppressive therapy in rheumatic diseases. Orientations for clinical practice.
Nunes J; Marinho RT; Fonseca JE; Pereira da Silva JA; Velosa J
Acta Reumatol Port; 2011; 36(2):110-8. PubMed ID: 21841730
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B infection and changes in interferon-alpha and -gamma production in patients with systemic lupus erythematosus in Taiwan.
Lu CL; Tsai ST; Chan CY; Hwang SJ; Tsai CY; Wu JC; Lu RH; Lin BC; Lee SD
J Gastroenterol Hepatol; 1997 Apr; 12(4):272-6. PubMed ID: 9195365
[TBL] [Abstract][Full Text] [Related]
9. [Rheumatoid arthritis and viral hepatitis].
Kobayashi H; Watanabe H; Ohira H
Nihon Rinsho; 2016 Jun; 74(6):1007-11. PubMed ID: 27311193
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
11. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?
Rodríguez-Torres M; Gonzalez-Garcia J; Bräu N; Solá R; Moreno S; Rockstroh J; Smaill F; Mendes-Correa MC; DePamphilis J; Torriani FJ;
J Med Virol; 2007 Jun; 79(6):694-700. PubMed ID: 17457912
[TBL] [Abstract][Full Text] [Related]
12. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus infection in patients with systemic lupus erythematosus.
Chng HH; Fock KM; Chew CN; Guan R; Feng PH; Boey ML; Chee EN; Chua KL
Singapore Med J; 1993 Aug; 34(4):325-6. PubMed ID: 8266204
[TBL] [Abstract][Full Text] [Related]
14. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence.
Inuzuka T; Ueda Y; Morimura H; Fujii Y; Umeda M; Kou T; Osaki Y; Uemoto S; Chiba T; Marusawa H
J Hepatol; 2014 Sep; 61(3):492-501. PubMed ID: 24798622
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study.
Lin WT; Chen YM; Chen DY; Lan JL; Chang CS; Yeh HZ; Yang SS
Lupus; 2018 Jan; 27(1):66-75. PubMed ID: 28534427
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
17. Presence of anti-HBc is associated to high rates of HBV resolved infection and low threshold for Occult HBV Infection in HIV patients with negative HBsAg in Chile.
Vargas JI; Jensen D; Sarmiento V; Peirano F; Acuña P; Fuster F; Soto S; Ahumada R; Huilcaman M; Bruna M; Jensen W; Fuster F
J Med Virol; 2016 Apr; 88(4):639-46. PubMed ID: 26381185
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
19. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B and C virus infection in patients with Systemic and Cutaneous Lupus Erythematosus.
Lo Presti A; Ceccarelli F; Dorrucci M; Farchi F; Pirone C; Garufi C; Valdarchi C; Spinelli FR; Alessandri C; Chionne P; Madonna E; Pisani G; Martina A; Simeoni M; Bruni R; Ciccozzi M; Iaiani G; Ciccaglione AR; Spada E; Conti F
New Microbiol; 2022 Dec; 45(4):296-303. PubMed ID: 36538293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
